On September 11, 2024, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for the treatment of moderate to severe active ulcerative colitis (UC).

Phanes Therapeutics reported that the first patient has received a dose in the clinical trial of PT886 alongside chemotherapy.

On September 11, 2024, Sanofi and Regeneron jointly announced that their pivotal study (ADEPT) of Dupilumab (Dupixent) for the treatment of adult patients with Bullous Pemphigoid (BP).

Clear Scientific Reveals Positive Initial Clinical Trial Results for CS-1103, a Novel Treatment for Meth and Fentanyl Overdose.

Ractigen Shares Encouraging Clinical Results for RAG-17 in ALS-SOD1 Therapy from Independent Study.

Insulin efsitora alfa, administered weekly, achieves comparable A1C reduction to daily insulin in adults with type 1 diabetes.

Recent findings on the investigational drug BAY 2927088 for HER2-mutant non-small cell lung cancer (NSCLC) showcased at WCLC.

Sep 13th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

In the TROPION-Lung01 Phase 3 trial, Datopotamab Deruxtecan demonstrated a median overall survival of 14.6 months for patients with advanced nonsquamous non-small cell lung cancer.

KaliVir is able to produce novel, potent oncolytic Vaccinia viruses with high replication ability and enhanced capabilities for intravenous administration and dissemination.

Incendia Therapeutics Begins Phase 1c Trial with First Patient for PRTH-101, an Innovative DDR1 Inhibitor.

Sep 12th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.